Cargando…

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

BACKGROUND: To understand the extent to which a large-scale healthcare claims database (DB) captures the safety profile of eribulin mesylate (Halaven(®), Eisai Co., Ltd., Japan), we compared patient characteristics, drug use, and adverse events (AEs) between data for patients treated with eribulin r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakata, Yukinori, Matsuoka, Toshiyuki, Ohashi, Satoshi, Koga, Tadashi, Toyoda, Tetsumi, Ishii, Mika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423272/ https://www.ncbi.nlm.nih.gov/pubmed/30847841 http://dx.doi.org/10.1007/s40801-019-0150-8

Ejemplares similares

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
por: Tsurutani, Junji, et al.
Publicado: (2018)

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data
por: Kawamura, Takahisa, et al.
Publicado: (2018)

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
por: Inoue, Kenichi, et al.
Publicado: (2020)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
por: Watanabe, Junichiro, et al.
Publicado: (2017)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
por: Hongo, Haruyuki, et al.
Publicado: (2021)

Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
por: Takahashi, Shunji, et al.
Publicado: (2020)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

National post-market surveillance assessment of veterinary medicines in Korea during the past decade
por: Kang, JeongWoo, et al.
Publicado: (2017)

Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan
por: NISHIKAWA, Ryo, et al.
Publicado: (2021)

Post-market quality assessment of 22 ciprofloxacin brands by HPLC available in Bangladesh market
por: Shohag, Md Hasanuzzaman, et al.
Publicado: (2023)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis
por: Ledent, Edouard, et al.
Publicado: (2016)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Post-marketing safety surveillance of the rotavirus vaccine in India
por: Kang, Gagandeep, et al.
Publicado: (2023)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

A flexible mixed‐data model applied to claims data for post‐market surveillance of prescription drug safety behavior
por: Butler, Harris, et al.
Publicado: (2022)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Post‐marketing monitoring of intussusception after rotavirus vaccination in Japan
por: Bauchau, Vincent, et al.
Publicado: (2015)

Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan
por: Asakura, Satoshi, et al.
Publicado: (2014)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
por: Fazeli Farsani, Soulmaz, et al.
Publicado: (2019)

Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation
por: Eguchi, Yutaka, et al.
Publicado: (2014)

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Post-marketing surveillance of anti-malarial medicines used in Malawi
por: Chikowe, Ibrahim, et al.
Publicado: (2015)

Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
por: Li, Chunxiao, et al.
Publicado: (2018)

Post marketing surveillance of selected veterinary medicines in Tanzania mainland
por: Fimbo, Adam M., et al.
Publicado: (2022)

Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study
por: Tamura, Mina, et al.
Publicado: (2022)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
por: Takata, Keiko, et al.
Publicado: (2022)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
por: Ito, Shuichi, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan
por: Tofukuji, Ayano, et al.
Publicado: (2023)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4koij2f7u0nljb796rdbkmuh23